On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
TuesdayMay 21, 2019 10:23 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) and Nuka to Expand Cannabis Product Operations for DehydraTECH Powered Edibles

Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) this morning announced that, through a major expansion in operations by Nuka Enterprises LLC, maker of 1906 cannabis edibles for high functioning adults, the most reliable fast acting edibles on the market will now be available across the country. According to the update, Nuka plans to exercise contractual options that it acquired last year for use of DehydraTECH(TM) technology through expanding operations for cannabis chocolates and edibles in six additional states and cannabis beverages in three states in 2019 and 2020. “Nuka's astonishing growth since launch is…

Continue Reading

ThursdayMay 16, 2019 12:24 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Responds to High Demand for Cannabis-Infused Beverages

The company aims to promote healthier administration methods, eliminating the need for sweeteners to mask taste Lexaria’s mission is to save lives with its technology, which allows for delivery of drug molecules through ingestible means The company is seeing high demand in North American markets for DehydraTECH in cannabis-infused beverages Lexaria recently announced its entry into a CBD-beverage formulation license agreement with a Nevada-based company Traditionally, consumers have relied on smoking to achieve higher absorption rates and fast onset of bioactive compounds such as nicotine and cannabinoids. Ingesting drugs and molecules through edibles is simply safer than inhaling them. However,…

Continue Reading

WednesdayMay 15, 2019 11:25 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH Outperforms Conventional Industry Formulations in Animal Testing

Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) this morning announced that animal testing has proven that its DehydraTECH(TM) technology delivers cannabinoids to the bloodstream much more quickly and effectively than conventional industry formulations. According to the update, 10 male Sprague-Dawley rats were administered CBD at 25mg per kg of bodyweight in each arm of the Lexaria animal studies. Delivery of CBD into the bloodstream was monitored over a 60-minute duration and, at two minutes, 15 minutes, and 60 minutes, DehydraTECH's LCFA formulation delivered elevated levels of CBD in blood (showing measurable and 475% and…

Continue Reading

TuesdayMay 14, 2019 12:30 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Adds Four Members to Advisory Board, Renews Executive Contracts

LXRP recently added multiple highly respected experts to its scientific advisory board The company is readying for growth by ensuring executive continuity LXRP continues to conduct research regarding oral nicotine Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has bolstered its future growth prospects by adding four new members to its scientific advisory board and renewing executive contracts with three-year compensation deals for key officers, including CEO Chris Bunka and President John Docherty. The agreements and new advisory board team members offer LXRP and its shareholders seamless executive continuity (http://ibn.fm/oBuUZ). New members of LXRP’s scientific advisory board include (http://ibn.fm/KSdJ3): Dr. Dwayne Godwin, dean…

Continue Reading

TuesdayMay 07, 2019 9:41 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enters CBD-Beverage Formulation License Agreement via Subsidiary

Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) this morning announced its entry into a definitive 5-year agreement, via its subsidiary Lexaria Hemp Corp. Under the agreement, Lexaria will provide its patented DehydraTECH(TM) technology to a private Nevada-based company for utilization in certain CBD-based beverages that will be produced and sold across the U.S. Lexaria continues to experience strong demand for use of its technology for beverage applications in North American markets. Lexaria’s many existing US-granted patents protect DehydraTECH-enabled products, which may include any combination of ready-to-drink beverages such as non-alcoholic beers, wines and spirits,…

Continue Reading

MondayMay 06, 2019 10:57 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enters New Licensing Agreement, Strengthens Business Model

Lexaria continues to create a strong, revenue-generating business model to support its growing patent portfolio The company out-licenses disruptive delivery technology, giving licensees access to existing patents Lexaria entered into a new beverage license agreement with a California-based cannabis firm The company recently announced four new appointments to its scientific advisory board Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is a drug-delivery platform innovator with existing cannabinoid licensing agreements in Canada and the United States, as well as internationally. By out-licensing disruptive delivery technology DehydraTECH, the company has created a strong, revenue-generating business model and a growing patent portfolio. At…

Continue Reading

ThursdayMay 02, 2019 11:12 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Execs Sign Three-Year Contract Extensions, Ensuring Management Continuity

LXRP CEO Chris Bunka and President John Docherty have agreed to new, three-year contracts The new contract agreements are designed to provide management security with continuity of key officers The company recently canceled 1,140,000 stock options after negotiations with optionees Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has successfully negotiated new three-year compensation contracts with key officers Chris Bunka, CEO, and John Docherty, president. The agreements offer LXRP and its shareholders the security of pursuing corporate growth within a seamless transition by providing management continuity. The renewal agreements are retroactive to January 1, 2019 (http://ibn.fm/V8SmJ). The agreements offer both officers compensation…

Continue Reading

MondayApr 29, 2019 2:05 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Innovative Technology Improves Delivery of Nicotine, Cannabinoids

Biotechnology company and drug-delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has developed and out-licenses its pioneering-drug delivery platform DehydraTECH(TM), which improves the speed, taste and delivery of bioactive compounds, including nicotine and cannabinoids. A recent article discussing the company reads, “Furthermore, the DehydraTECH drug delivery platform increases bio-absorption by up to 10 times and lessens the time of onset, with effects being felt within 15 to 20 minutes, as compared to 60 to 120 minutes without the platform. In addition, the technology is patent protected for cannabidiol (CBD) and all other nonpsychoactive cannabinoids. Patents are also granted…

Continue Reading

ThursdayApr 25, 2019 9:45 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Expands Advisory Board; Subsidiary Enters Beverage License Agreement

Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) on Wednesday announced that, through its subsidiary Lexaria CanPharm ULC, it has entered a definitive 5-year agreement to provide Lexaria's patented DehydraTECH(TM) technology to a private California-based cannabis company. Under the agreement the cannabis company will utilize the technology in certain cannabis-based beverages to be produced and sold in the states of California and Nevada. DehydraTECH-enabled beverages are protected under Lexaria's many existing US-granted patents and may include any combination of ready-to-drink beverages such as non-alcoholic beers, wines and spirits; cold or hot coffee or teas, sports…

Continue Reading

MondayApr 15, 2019 12:10 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Advancing DehydraTECH Drug Delivery Platform, Innovative Products

Lexaria Bioscience is focusing on its pioneering DehydraTECH drug delivery technology The company boasts a portfolio of unique products Lexaria continues to conduct research regarding DehydraTECH technology for oral nicotine Based in Kelowna, British Columbia, Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) focuses on technology for the improved delivery of bioactive compounds. Lexaria is the only global company with patents issued for the oral delivery of all cannabinoids. The company has developed and out-licenses its innovative and cost-effective DehydraTECH drug delivery platform. This technology changes the way that edible cannabinoids enter the body. DehydraTECH delivery technology offers a viable and…

Continue Reading

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

The Basics

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

Register

Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

Get Covered